Global Bioprocessing Market Report, First Edition: 2024-2027

Download a sample of the report here.

The first edition of this report provides an overview of the bioprocessing manufacturer and CDMO / service market, separately, from 2024 to 2027. Bioprocessing manufacturers are split between those providing reagents / equipment only and those providing reagents, equipment, and CDMO services. Those focused on reagents / equipment often provide comprehensive offerings across upstream and downstream workflows, although some have taken a more niche pathway (e.g., Miltenyi Biotec in cell and gene therapy). Vendors providing both products and services (e.g., Cytiva, Thermo Fisher, Lonza) have made continuous strategic expansions, both organic and inorganic, to expand bioprocessing footprints globally to ensure end-to-end support for customers. CDMO only providers often aim to provide services from discovery to formulation (e.g., WuXi, Samsung), while others specialize in more niche areas (e.g., plasmid production).

After the post–COVID boom, the bioprocessing market faced a slowdown as early-stage R&D and clinical production contracted globally, limiting pipeline expansion. In 2024, however, the market returned to growth, with momentum expected to continue. While geopolitical uncertainty and a fragmented regulatory landscape remain headwinds, growth is fueled by innovation in novel modalities, workflow streamlining technologies, and expanding CDMO capacity. Balancing these dynamics, we project the manufacturer market will grow from ~$17B today to ~$22B by 2027 (9% CAGR), while the CDMO / service market will expand from ~$12B to ~$17B over the same period (12% CAGR).

This report is informed by a comprehensive primary and secondary analysis, including N = 23 interviews across manufacturers and CDMO KOLs and pharma end-users and a thorough investigation of company filings, investor presentations, and earnings calls. Further analysis of pharma pipelines, clinical trial activity, and macroeconomic trends were also completed. The market model is a top-down model based on the reported revenue of top bioprocessing vendors (manufacturers and CDMOs), segmented across key application segments. We triangulated market growth using historical and forecasted organic growth predictions from top players.

The report also includes in depth analysis, stakeholder perception, and vendor takeaways for each notable trend in the bioprocessing space, as well as thorough workflow outlines for each modality included in the report (e.g., mAbs, complex antibodies, cell therapies, gene therapies, vaccines, small peptides). Comprehensive company profiles detailing competitive positioning, product offerings, and recent activity are also included.  

*Some of the companies listed in the report may be DeciBio Consulting clients and customers

‍

‍

Segmentations Covered in Market Analysis:

Modalities

• Monoclonal Antibodies

• Complex Antibodies (e.g., ADCs, bi- and tri-specifics)

• Cell Therapies

• Gene Therapies

• Vaccines

• Small Peptides

• Other

‍

Customer Type

• Pharma

• CDMO / CRO

• Industry (e.g., food, beverage)

‍

Process Stage

• Upstream

• Downstream

‍

Workflow Mode

• Batch

• Hybrid

• Continuous

‍

Competitors

• Danaher

• Merck Millipore

• Sartorius

• Thermo Fisher

• Lonza

• WuXi Biologics

• Samsung Biologics

• More